Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor

NCT05079360 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT05079360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05079360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Lead sponsor
Veru Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
March 15, 2023
Completion date
May 26, 2024
Enrollment
0 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer